login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
CORMEDIX INC (CRMD) Stock News
USA
-
Nasdaq
- NASDAQ:CRMD -
US21900C3088
-
Common Stock
11.33
USD
-0.16 (-1.39%)
Last: 12/15/2025, 4:15:38 PM
11.4356
USD
+0.11 (+0.93%)
After Hours:
12/15/2025, 4:15:38 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
CRMD Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: Chartmill
CorMedix Inc (NASDAQ:CRMD) Shows Explosive Growth Metrics in "Little Book" Screen
6 days ago - By: Zacks Investment Research
- Mentions:
AGIO
ANIP
CSTL
Agios Awaits Pyrukynd Decision in Thalassemia as FDA Misses Due Date
6 days ago - By: Zacks Investment Research
Does CorMedix (CRMD) Have the Potential to Rally 68.74% as Wall Street Analysts Expect?
6 days ago - By: Zacks Investment Research
- Mentions:
COR
Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?
7 days ago - By: Zacks Investment Research
CorMedix (CRMD) Upgraded to Strong Buy: Here's What You Should Know
7 days ago - By: Zacks Investment Research
- Mentions:
ANIP
ARQT
PRAX
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know
7 days ago - By: Zacks Investment Research
- Mentions:
INCY
ANIP
ARQT
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
7 days ago - By: Zacks Investment Research
- Mentions:
GM
AER
Best Value Stocks to Buy for December 8th
7 days ago - By: Zacks Investment Research
- Mentions:
GM
FIVE
AER
VFF
New Strong Buy Stocks for December 8th
10 days ago - By: Zacks Investment Research
- Mentions:
ANIP
ARQT
ABSI
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
10 days ago - By: Zacks Investment Research
- Mentions:
ANIP
CAPR
ARQT
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
10 days ago - By: Zacks Investment Research
- Mentions:
PFE
AMPH
Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?
11 days ago - By: Zacks Investment Research
- Mentions:
BMY
FOLD
ANIP
BMY Gains on News of Continuation of Alzheimer's Disease Study
11 days ago - By: Zacks Investment Research
- Mentions:
ZTS
ADMA
ARQT
Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know
12 days ago - By: Zacks Investment Research
- Mentions:
JNJ
ANIP
Bayer Stock Up as Government Backs Supreme Court Review in Roundup Case
12 days ago - By: Zacks Investment Research
- Mentions:
PCRX
ADMA
ARQT
PCRX's Iovera Outperforms RFA Therapy in Pilot Study for Low Back Pain
12 days ago - By: Zacks Investment Research
- Mentions:
AZN
ADMA
ARQT
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension
13 days ago - By: Zacks Investment Research
- Mentions:
REGN
ANIP
REGN & Tessera Collaborate to Develop Gene-Editing Therapy for AATD
13 days ago - By: Zacks Investment Research
- Mentions:
FOLD
ANIP
BHC
BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business
13 days ago - By: Zacks Investment Research
- Mentions:
ADMA
MIRM
ARQT
MIRM Enrolls First Patient in Phase II Fragile X Syndrome Study
13 days ago - By: Zacks Investment Research
- Mentions:
JNJ
ADMA
ARQT
JNJ Gets EU Nod for Imaavy in Generalized Myasthenia Gravis
14 days ago - By: Zacks Investment Research
- Mentions:
ARCT
ADMA
ARQT
ARCT Stock Plunges 59% in Three Months: Here's What You Need to Know
25 days ago - By: Zacks Investment Research
- Mentions:
ALKS
AGIO
FULC
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
25 days ago - By: Zacks Investment Research
- Mentions:
ALKS
AVDL
CSTL
ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal
a month ago - By: Zacks Investment Research
- Mentions:
ALKS
INSM
CSTL
Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri
a month ago - By: Zacks Investment Research
- Mentions:
ALKS
JAZZ
ZYME
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
a month ago - By: Zacks Investment Research
- Mentions:
ALKS
AVDL
CSTL
Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal
a month ago - By: Zacks Investment Research
- Mentions:
ALKS
SRPT
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings
a month ago - By: The Motley Fool
- Mentions:
ACRX
Talphera (TLPH) Q3 2025 Earnings Call Transcript
a month ago - By: Stocktwits
CorMedix Stock Breaks Out To 2-Month High: Analysts Reset Price Targets After Blowout Q3 And Surging DefenCath Demand
a month ago - By: Talphera, Inc.
- Mentions:
TLPH
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
a month ago - By: Benzinga
CorMedix Q3 Profit Soars As DefenCath Dialysis Demand Exceeds Expectations
a month ago - By: Benzinga
- Mentions:
IMOS
PERI
PHAR
MH
...
Pharming Group Posts Upbeat Q3 Results, Joins On Holding, BigBear.ai Holdings And Other Big Stocks Moving Higher On Wednesday
a month ago - By: Stocktwits
- Mentions:
VFMO
IWMW
Cormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance
a month ago - By: CorMedix, Inc.
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
a month ago - By: Zacks Investment Research
- Mentions:
ALKS
FOLD
IMVT
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Please enable JavaScript to continue using this application.